SCHEMBL5129230

SCHEMBL5129230

C#Cc1ccsc1-c1nc2cc(C)ccn2c1NC(C)c1ccccc1.c1cc2cc-2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 3/20 0.44
GAA P10253 9/20 0.41
MAPT P10636 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 3/20 0.41
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PKM P14618 1/20 0.38
PKLR P30613 1/20 0.38
GFER P55789 1/20 0.38
BRD4 O60885 1/20 0.38
ATM Q13315 1/20 0.36
HTT P42858 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128154 0.88 NR1H4 (0.59) NR1H4GAASMN1; SMN2TP53KDM4E
SCHEMBL5122233 0.87 BRD4 (0.50) NR1H4GAAMAPTSMN1; SMN2TP53
SCHEMBL5127885 0.86 MAPK14 (0.42) NR1H4SMN1; SMN2NPC1RAB9ABRD4
SCHEMBL5122906 0.86 NR1H4 (0.40) NR1H4GAAMAPTSMN1; SMN2TP53
SCHEMBL5116602 0.84 GAA (0.40) NR1H4GAAMAPTSMN1; SMN2TP53
SCHEMBL5127031 0.78 ALDH1A1 (0.50) NR1H4GAAMAPTSMN1; SMN2TP53
SCHEMBL5127697 0.78 MAPT (0.44) NR1H4GAAMAPTSMN1; SMN2TP53
SCHEMBL5122972 0.77 ATP4A (0.40) NR1H4CYP1A2CYP3A4CYP2C9KMT2A
SCHEMBL5130393 0.77 GAA (0.51) NR1H4GAAMAPTSMN1; SMN2TP53
SCHEMBL5129077 0.77 ATM (0.43) NR1H4GAAMAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS NR1H4 2683/4885GAA 234/4885MAPT 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.